Literature DB >> 1213649

Glucose, insulin, pancreatic glucagon and glucagon-like immunoreactive materials in the plasma of normal and diabetic children. Effect of the initial insulin treatment.

T Matsuyama, W H Hoffman, J C Dunbar, N L Foà, P P Foà.   

Abstract

Pancreatic glucagon (PG) and other glucagon-like immunoreactive materials (GLI) were measured in the plasma of normal and of newly diagnosed untreated diabetic children, using an antiglucagon serum (AGS) highly specific for pancreatic glucagon (AGS 18) and an AGS which crossreacts with extracts of intestinal mucosa (AGS 10). Gut GLI was considered to be the difference between "total" GLI (AGS 10) and PG (AGS 18). Glucose and immunoreactive insulin (IRI) were also measured. PG, total GLI and gut GLI were significantly elevated in children with severe insulin insufficiency and were reduced to normal by insulin treatment, even though a significant fasting hyperglycemia was still present. In three diabetic children who had high initial plasma IRI levels the three glucagon fractions were normal. We conclude that insulin insufficiency is characterized not only by high plasma levels of PG as previously reported, but also of gut GLI. These abnormalities can be corrected by the administration of insulin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1213649     DOI: 10.1055/s-0028-1093702

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

1.  Plasma glucagon and glucagon-like immunoreactive components in Type 1 (insulin-dependent) diabetic patients and normal subjects before and after an oral glucose load.

Authors:  A Rovira; F J Garrote; J M Pascual; M G Salvador; J L Herrera Pombo; I Valverde
Journal:  Diabetologia       Date:  1985-02       Impact factor: 10.122

2.  Regulation of brittle diabetics by a pre-planned insulin infusion programme.

Authors:  T Deckert; B Lorup
Journal:  Diabetologia       Date:  1976-12       Impact factor: 10.122

Review 3.  Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.

Authors:  Claire M Issa; Sami T Azar
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

4.  The serum glucose response to glucagon suppression with somatostatin, insulin or antiglucagon serum in depancreatized rats.

Authors:  J C Dunbar; M F Walsh; P P Foà
Journal:  Diabetologia       Date:  1978-01-14       Impact factor: 10.122

5.  Letter to the Editor: Endocrine and metabolic emergencies in children: hypocalcemia, hypoglycemia, adrenal insufficiency, and metabolic acidosis including diabetic ketoacidosis.

Authors:  Viktor Rosival
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-06-30

6.  Management of adult diabetic ketoacidosis.

Authors:  Viktor Rosival
Journal:  Diabetes Metab Syndr Obes       Date:  2014-11-28       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.